Ranly Don M, Lohmann Christoph H, Andreacchio Domenico, Boyan Barbara D, Schwartz Zvi
Wallace H Coulter Department of Biomedical Engineering, Georgia Institute of Technology, 315 Ferst Drive NW, Atlanta, GA 30332-0363, USA.
J Bone Joint Surg Am. 2007 Jan;89(1):139-47. doi: 10.2106/JBJS.F.00388.
It is unclear whether platelet-rich plasma is a clinically effective adjunct to osteoinductive agents such as demineralized bone matrix. It contains platelet-derived growth factor (PDGF), which decreases osteoinduction by human demineralized bone matrix in nude-mouse muscle, suggesting that platelet-rich plasma may also have a negative impact. This study tested the hypothesis that platelet-rich plasma reduces demineralized bone matrix-induced bone formation and that this effect varies with donor-dependent differences in platelet-rich plasma and demineralized bone matrix.
Human platelet-rich plasma was prepared from blood from six men (average age [and standard error of the mean], 29.2 +/- 2.4 years). Platelet numbers were determined, and growth factors were quantified before and after platelet activation. Human demineralized bone matrix from two donors (demineralized bone matrix-1 and demineralized bone matrix-2) was mixed with activated platelet-rich plasma and was implanted bilaterally in the gastrocnemius muscle in eighty male nude mice (eight implants per variable). Fifty-six days after implantation, the hindlimb calf muscles were harvested for histological analysis. Osteoinduction was evaluated with use of a qualitative score and morphometric measurements of ossicle size, new bone formation, and residual demineralized bone matrix.
Compared with platelet-poor plasma, platelet-rich plasma preparations exhibited a fourfold increase in the platelet count, a fifteenfold increase in the amount of transforming growth factor-beta, a sixfold increase in the amount of PDGF-BB, a fivefold increase in the amount of PDGF-AA, and a twofold increase in the amount of PDGF-AB. Demineralized bone matrix-1 was more osteoinductive than demineralized bone matrix-2, as determined on the basis of a greater ossicle area. The effect of platelet-rich plasma was either neutral or inhibitory depending on the demineralized bone matrix batch. When used with demineralized bone matrix-1, platelet-rich plasma did not alter the qualitative score or overall ossicle size, but it decreased the new bone area. When used with demineralized bone matrix-2, platelet-rich plasma reduced the qualitative score, ossicle area, and new bone area and increased the amount of residual demineralized bone matrix. The effects on osteoinduction also varied with the donor of the platelet-rich plasma.
Platelet-rich plasma decreased the osteoinductivity of demineralized bone matrix implanted in immunocom-promised mice, and the activities of both demineralized bone matrix and platelet-rich plasma were donor-dependent.
富血小板血浆作为一种辅助骨诱导剂(如脱矿骨基质)是否具有临床疗效尚不清楚。富血小板血浆含有血小板衍生生长因子(PDGF),该因子可降低脱矿骨基质在裸鼠肌肉中的骨诱导作用,提示富血小板血浆可能也有负面影响。本研究验证了以下假设:富血小板血浆会降低脱矿骨基质诱导的骨形成,且这种作用会因富血小板血浆和脱矿骨基质供体的差异而有所不同。
从6名男性(平均年龄[及平均标准误差],29.2±2.4岁)的血液中制备人富血小板血浆。测定血小板数量,并对血小板激活前后的生长因子进行定量。将来自两名供体的人脱矿骨基质(脱矿骨基质-1和脱矿骨基质-2)与激活的富血小板血浆混合,双侧植入80只雄性裸鼠的腓肠肌中(每个变量植入8处)。植入56天后,取后肢小腿肌肉进行组织学分析。通过定性评分以及对小骨大小、新骨形成和残余脱矿骨基质的形态学测量来评估骨诱导作用。
与贫血小板血浆相比,富血小板血浆制剂的血小板计数增加了4倍,转化生长因子-β的量增加了15倍,血小板衍生生长因子-BB的量增加了6倍,血小板衍生生长因子-AA的量增加了5倍,血小板衍生生长因子-AB的量增加了2倍。根据更大的小骨面积判断,脱矿骨基质-1比脱矿骨基质-2的骨诱导性更强。富血小板血浆的作用根据脱矿骨基质批次的不同而呈中性或抑制性。当与脱矿骨基质-1一起使用时,富血小板血浆不会改变定性评分或小骨的总体大小,但会减小新骨面积。当与脱矿骨基质-2一起使用时,富血小板血浆会降低定性评分、小骨面积和新骨面积,并增加残余脱矿骨基质的量。对骨诱导的影响也因富血小板血浆的供体不同而有所差异。
富血小板血浆降低了植入免疫功能低下小鼠体内的脱矿骨基质的骨诱导能力,且脱矿骨基质和富血小板血浆的活性均依赖于供体。